NRP1 and neoplasm: A novel peptide drug conjugate called ER-472, comprised of CTX linked to a cryptophycin analog, was found to possess antitumor activity related to NRP1 expression levels in xenografts, and its potency was significantly reduced following treatment with NRP-1 blocking antibodies or following knockout in tumor cells, confirming a role for NRP1-binding in ER-472 activity [54].